Sarepta Therapeutics (SRPT) Tops Q2 EPS by 45c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.46), $0.45 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $35 million versus the consensus estimate of $22.38 million.

Guidance:

Raises FY2017 guidance to $125-130 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters